Six Steps to Fix Our Public Health Agencies’ Testing Capabilities in the Pandemic

By  George Poste

October 12, 2020

The following piece is adapted from a panel discussion on Day 2 of the 2020 Future Security Forum: Reimagining National Security in the Age of COVID-19, featuring remarks from ASU’s Chief Scientist, Complex Adaptive Systems Initiative’s George Poste.

As COVID-19 cases in the United States surge over 7 million and daily case numbers hover around 40,000—now, more than ever, is a time to reflect upon our country’s diagnostic preparedness. From the very beginning, the current administration was and continues to be ill-prepared to handle the crisis. Politics notwithstanding, questions still persist surrounding our public health agencies’ testing capabilities and response to the pandemic.

Too often, testing is the most neglected component in the myriad patterns of neglect across the entire bio preparedness spectrum. To address some of the main issues we should be tackling during this pandemic and others to come, we must address six key components of diagnostics preparedness—otherwise known as the six S’s.

The first “S” is real time situational awareness; without that, we are stumbling blindly into a crisis. Unless we understand the prevalence of a disease and its patterns of spread, we will not know how to act proactively.

The next S is surveillance, more specifically, global biosurveillance. We need to assess the threat of disease and its behavior in different environments. As COVID-19 and many other recent novel infections illustrate the spillover of viruses into people from animal reservoirs of infections (zoonoses) is a crucial problem.

The third S is speed. Once an illness is in our midst—or is suspected to be—we need to mobilize rapidly. Unfortunately, what we saw from the Centers for Disease Control and Prevention, was an abject failure, both as a combination of technical incompetence, as well as hubris and arrogance in the agency’s belief that they could produce a superior test to the WHO or academic laboratories. The CDC wasted vital time in the pursuit of a COVID-19 test, slowing down our ability to quickly handle the emerging crisis.

The fourth S is scale. Even when a robust and reproducible test is developed, the scale and planning for large scale distribution must be in place. We need the infrastructure to both manufacture and distribute the test across a network of centralized mega-laboratories capable of very high throughput and distribution to hot spots where the test is most needed.

The logistical challenges presented are daunting. According to various estimates, we may need upwards of 6 million tests per day to guide us through the upcoming fall and winter. The CDC, in addition to its initial ineptitude, should have been far more proactive in engaging the private sector. There’s a critical lesson here, not just for diagnostics but for all aspects of preparedness: therapeutics, vaccines, PPE, ventilators, planning for potential hospital overloads and the need to protect vulnerable populations such as nursing homes. U.S. government agencies have been negligent in failing to engage the private sector in a suitably proactive way for rapid mobilization for multiple critical needs.

The fifth S relates to standards and regulatory oversight of diagnostic test performance. The FDA dropped the ball by offering multiple emergency use authorizations without adequate scrutiny of their performance. As a consequence, the United States became a wild west of testing. Suddenly, a floodgate of tests, many of dubious value and widely varying accuracy, entered the market.

The last S is systems. Diagnostics are but one part of a complex, integrated matrix of technologies, organizations and supply chains that must be mobilized in a pandemic. Interagency coordination within government is fundamental in this response. And, at this moment, it is performing badly, notwithstanding any additional complexities created by the intrusion of misplaced political interference. There continues to be unclear accountability and decision authorities which has created problems that pervade all elements of the domestic response. In addition to the U.S. response there is a parallel need for coherent international coordination, not just in diagnostics, but in recognizing the need for a systems-based approach to integrate the complex and diverse activities needed to curtail the pandemic.

Originally published on

Read the article »

Geneticist, informatics expert Buetow to lead new research program at ASU

Kenneth H. Buetow, a human geneticist and former director of the Center for Biomedical Informatics and Information Technology at the National Cancer Institute, is joining Arizona State University as director of Computational Sciences and Informatics in the Complex Adaptive Systems Initiative. He will hold the rank of full professor in the School of Life Sciences in ASU’s College of Liberal Arts and Sciences. His appointment is effective March 5. The Complex Adaptive Systems Initiative (CASI) was established in 2009 to leverage ASU’s interdisciplinary research strengths on complex global challenges where an integrated cross-disciplinary effort is essential. The establishment of the Computational Sciences and Informatics program in CASI will represent a major foundational resource in this effort by developing world class computing and modeling expertise and capabilities with breadth and depth in key areas such as agent base modeling, visualization, algorithm development and expert systems in healthcare, the environment and national security. Read the article »

ASU experts grapple with gene-based medicine questions on PBS

Sooner than we think, we will have access to our own genetic codes. Are we ready to join the DNA generation? Two ASU researchers, Gary Marchant and George Poste, will tackle legal and ethical dilemmas surrounding personalized medicine on “Arizona Horizon” at 5:30 p.m., March 28, on Eight, Arizona PBS. That same evening, Eight will premiere the new NOVA program “Cracking Your Genetic Code” at 8 p.m. Read the article »

The way we do science: saving America’s knowledge enterprise

Future Tense forum – “How to Save America’s Knowledge Enterprise from Tight Budgets, Primitive Myths & the Shadow of Albert Einstein” – scheduled for 12 to 5:30 p.m., May 21, at the New America Foundation in Washington, D.C. Sarewitz joins other scholars, including George Poste, chief scientist of ASU’s Complex Adaptive Systems Initiative, and founder and former director of the Biodesign Institute at ASU; Jonathan Koppell, director of ASU’s School of Public Affairs and dean of the College of Public Programs; and ASU President Michael Crow. Read the article »

2012 Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development

George Poste, David P. Carbone, David R. Parkinson, et al. Clin Cancer Res 2012;18:1515-1523. Published online March 14, 2012. Abstract: Molecular diagnostics are becoming increasingly important in clinical research to stratify or identify molecularly profiled patient cohorts for targeted therapies, to modify the dose of a therapeutic, and to assess early response to therapy or monitor patients. Molecular diagnostics can also be used to identify the pharmacogenetic risk of adverse drug reactions. Read the article »

ASU expertise in analytics helps bring major international conference to Phoenix

“Among featured speakers will be ASU professors George Poste and Edward Prescott. Poste is an ASU Regents’ Professor, chief scientist of the university’s Complex Adaptive Systems Initiative and the Del E. Webb Chair in Health Innovation. He’ll focus on the role of analytical and computational systems in meeting challenges and creating opportunities in personalized medicine.” Read the article »

Inaugural Workshop: National Biomarker Development Alliance (NBDA)

The NBDA inaugural workshop is Workshop I in a series that will, over the next several months, bring together groups of experts from all sectors to specifically identify the level of interests standards needed to build a rational (and predictable) biomarker development pipeline. The NBDA, which is hosted by Arizona State University (ASU), currently consists of three founding partners, ASU, the Critical Path Institute (C-Path) and the International Genome Consortium (IGC). Workshop I, is scheduled for December 13 -14, 2012, at the Camelback Inn, Scottsdale, AZ Read the article »

Member, International Ebola Vaccine Team B Report (2015) “Osterholm, M. et al. (2015) The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. Lancet Infect. Dis.

Members listed at the end of the paper. Published Online: 30 October 2015 Read the article »

Dr. George Poste speaking at the PMWC 2017 Silicon Valley

(co-hosted by Stanford, UCSF, Intermountain Healthcare) on January 23-25, 2017. Read the article »

Dr. George Poste Speaking at The Cambridge Healthtech Institute’s Biomarkers and Immuno-Oncology World Congress, May 2-4, 2017

Dear Colleague. I am giving a talk at Cambridge Healthtech Institute’s Biomarkers and Immuno-Oncology World Congress, May 2-4, 2017 in Philadelphia. The congress features more than 100 speakers in 6 programs and 7 short courses. View detailed agenda or register here: Read the article »